|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
ophthalmologist
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:Eylea
gptkb:Avastin
|
|
gptkbp:ATCCode
|
S01LA04
|
|
gptkbp:biosimilar
|
gptkb:Byooviz
gptkb:Cimerli
|
|
gptkbp:CASNumber
|
gptkb:347396-82-1
|
|
gptkbp:contraindication
|
hypersensitivity to ranibizumab
ocular or periocular infection
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:drugClass
|
monoclonal antibody fragment
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:ranibizumab
|
|
gptkbp:halfLife
|
9 days (in vitreous)
|
|
gptkbp:hasMolecularFormula
|
C2158H3310N566O681S12
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lucentis
|
|
gptkbp:indication
|
gptkb:wet_AMD
diabetic retinopathy
glaucoma
|
|
gptkbp:legalStatus
|
prescription only
patent expired in US (2020)
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
VEGF-A inhibitor
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:product
|
humanized monoclonal antibody fragment
|
|
gptkbp:routeOfAdministration
|
intravitreal injection
|
|
gptkbp:sideEffect
|
conjunctival hemorrhage
eye pain
increased intraocular pressure
retinal detachment
intraocular inflammation
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:vascular_endothelial_growth_factor_A
|
|
gptkbp:UNII
|
X82T1D6AYX
|
|
gptkbp:usedFor
|
gptkb:diabetic_macular_edema
age-related macular degeneration
macular edema following retinal vein occlusion
myopic choroidal neovascularization
|
|
gptkbp:website
|
https://www.lucentis.com/
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|